Skip to content
value.today

Basking Biosciences, Inc.

Total raised
$57 M
2 rounds on record
Latest round
$55 M
Oct 2023
First round on record
Aug 2020
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Basking Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2023$55 MNo. 2$50 to $250 million

Basking Biosciences, Inc.: Raise no. 2, Oct 2023

Investors in this round

11 investors had bought by the notice of Oct 22, 2025: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$55 M of $55 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Julia Owens · Executive Officer, Director, Promoter
  • Aiden Aceves · Director
  • Ari Nowacek · Director
  • David Adair · Director
  • Hannah Chang · Director
  • Shahid Nimjee · Director
  • Steve Gillis · Director
  • Thomas Needham · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital, which may include normal compensation to executive officers.”

Signed by Julia Owens, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Oct 22, 2025. Read the notice at the SEC.

equitySEC
Aug 2020$2 MNo. 1Under $2 million

Basking Biosciences, Inc.: Raise no. 1, Aug 2020

Investors in this round

6 investors had bought by the notice of Sep 10, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $7 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in North Carolina

People named in the notice

  • Richard Shea · Executive Officer, Director, Promoter
  • Bruce Sullenger · Director
  • Dan Myers · Director
  • Ryan Helon · Director
  • Shahid Nimjee · Director
  • Thomas Needham · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital, which may include normal compensation to executive officers.”

Signed by Richard Shea, Ceo. Source: SEC Form D, newest notice filed Sep 10, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Basking Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2025).

    SEC Form D · Oct 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2025

That is all the official record says: Basking Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Basking Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 11 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Basking Biosciences, Inc.
NameRoleNamed in
Julia OwensExecutive officerOct 2025
Richard SheaExecutive officerNov 2023
Aiden AcevesDirectorOct 2025
Ari NowacekDirectorOct 2025
David AdairDirectorOct 2025
Hannah ChangDirectorOct 2025
Julia OwensDirectorOct 2025
Shahid NimjeeDirectorOct 2025
Steve GillisDirectorOct 2025
Thomas NeedhamDirectorOct 2025
Richard SheaDirectorNov 2023
Bruce SullengerDirectorSep 2020
Dan MyersDirectorSep 2020
Ryan HelonDirectorSep 2020
Julia OwensPromoterOct 2025
Richard SheaPromoterNov 2023